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Abstract
Background: UK Dementia Strategies prioritise fair access to mental and physical healthcare. We investigated whether
there are inequalities by deprivation or gender in healthcare received by people with dementia, and compared healthcare
received by people with and without dementia.
Methods: we investigated primary care records of 68,061 community dwelling dementia patients and 259,337 people with-
out dementia (2002–13). We tested hypotheses that people with dementia from more deprived areas, and who are women
receive more psychotropic medication, fewer surgery consultations, are less likely to receive annual blood pressure, weight
monitoring and an annual review, compared with those from less deprived areas and men.
Results: only half of people with dementia received a documented annual review. Deprivation was not associated with health-
care received. Compared to men with dementia, women with dementia had lower rates of surgery consultations (adjusted inci-
dence rate ratio (IRR) 0.90, 95% CI 0.90–0.91), of annual blood pressure monitoring (adjusted IRR 0.96, 95% CI 0.95–0.97)
and of annual weight monitoring (adjusted IRR 0.91, 95% CI 0.90–0.93). Men with dementia were less likely to be taking psy-
chotropic medication than women with dementia. People with dementia had fewer surgery consultations and were less likely to
have their weight and blood pressure monitored at least annually, compared to the non-dementia group.
Conclusions: people with dementia, in particular women, appear to receive less primary healthcare, but take more psycho-
tropic medication that may negatively impact their physical health. Reducing these inequalities and improving access of peo-
ple with dementia to preventative healthcare could improve the health of people with dementia.
Keywords: dementia, healthcare disparities, deprivation, psychotropic drugs, equalities, medication, older people
Introduction
People with dementia have high rates of physical ill-health,
most commonly hypertension and diabetes [1] and of neuro-
psychiatric symptoms, that may be treated with psychotropic
medication, including antipsychotics [2–4]. Mental and phys-
ical well-being are key determinants of life quality and
independent living in dementia [5]. Improving physical health
may slow cognitive decline, by reducing cardiovascular path-
ology or functional impairment and improving diabetic
control [6].
In dementia, antipsychotic prescribing is associated with
cognitive decline [7], mortality [8], side effects, somnolence
and falls [9] and hypnotics and anxiolytics with cognitive
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decline [10, 11] and falls [9]. In 2009, the UK Medicines
and Healthcare products Regulatory Agency (MHRA) high-
lighted risks of stroke and death with antipsychotics [12],
and a UK government-commissioned review prioritised
reducing their use in dementia [13]; UK usage has fallen
since these publications [14–16].
People with dementia may be at increased risk of social
inequalities. The reduced access to healthcare typical of the
oldest old, women and those with fewer socio-economic
resources may compound communication difﬁculties and
social isolation in people with dementia [17]. Socio-
economic factors may be implicated in dementia aetiology
[1]. Lower levels of education and worse physical health,
which are strongly linked to deprivation, are associated with
a greater dementia risk [2, 3]. Among people with dementia
those from more deprived areas, women and older people
are relatively less likely to receive anti-dementia drugs [18].
We aimed to investigate whether there are also social
inequalities in physical preventative healthcare provision
and psychotropic drug prescribing among people with
dementia, and to compare these outcomes in people with
and without dementia. We hypothesised, based on previous
ﬁndings, that women and people from more deprived areas
would access physical and mental healthcare less than their
counterparts [4, 5]. We selected variables from The Health
Improvement Network (THIN) primary care database to
test these hypotheses, constrained by data availability. We
judged that people with reduced healthcare access would be
less likely to receive a dementia review, and more likely to
be taking psychotropic medication, because medication for
short-term treatments of challenging behaviour would be
less frequently reviewed. We tested our hypotheses that
people with dementia from more deprived areas, and
women receive [1] more psychotropic medication [2], fewer
surgery consultations [3], are less likely to have had blood
pressure and weight monitoring and [4] an annual dementia
review recorded in the last year, compared with those from
less deprived areas and men.
Methods
Data
THIN primary care database contains anonymised informa-
tion on twelve million patients from over 500 participating
UK general practices (http://www.csdmruk.imshealth.com).
General Practitioners (GPs) record information on symp-
toms and medical diagnoses using the Read hierarchical clas-
siﬁcation system [19], and information on prescriptions is
entered onto the system automatically. Demographic infor-
mation recorded for each patient includes sex, year of birth
and Townsend deprivation score quintiles (see details below).
Study population
Individuals included in the study were under follow-up
while aged 50 years or over during the period 2002–13, and
had dementia, deﬁned as a Read code for dementia
(see Appendix 1 for code list) or an anti-dementia drug pre-
scription (galantamine, rivastigmine, donepezil or meman-
tine). We excluded individuals for whom deprivation score
quintile data were not available (2%). For each practice, only
data from the date of acceptable levels of computer usage
and death recording were included, as inadequate recording
of events before these dates may lead to incidence being
underestimated [20, 21].
In this study, our focus was on people who were living
outside long-term care facilities. We identiﬁed and excluded
individuals who were likely to be resident in a long-term care
facility, based on the assumption that households with ﬁve or
more residents aged 70 or over on 1 January 2010 were such
facilities. For the psychotropic drug prescribing prevalence
and healthcare contact outcomes, patient data were addition-
ally required to contain at least 6 months of follow-up. For
each patient in the dementia cohort, we used a frequency
matching approach to randomly select up to ﬁve patients not
in the dementia cohort who were in the same practice, age
group and the same sex at the start of follow-up.
Measurements
A list of Read codes for dementia diagnoses was developed
using a published method [22]. We studied deprivation
using Townsend score quintiles [23]. This area-level depriv-
ation measure is calculated at the level of UK postcodes,
using 2001 census data on unemployment, car ownership,
home ownership and home overcrowding: quintiles are
based on the whole UK population. Prescription data were
used to determine initiation of antipsychotics, hypnotics
and anxiolytics. Healthcare contact outcomes were, over a
year: (i) number of surgery consultations; (ii) whether blood
pressure and weight had been measured; (iii) whether there
was a record that an annual dementia review (as required
for the Quality Outcome Framework (QOF) payment [24])
had occurred. Reviews involve assessment of physical and
mental health. Prevalence of an outcome was deﬁned for
each 1-year period as the proportion of those under follow-
up during that period who had the outcome during that
year. Covariates included sex, UK country, age, and, for the
healthcare contact outcomes, a prescribing index as a meas-
ure of comorbidity (see details below). Age was analysed in
10-year categories. The prescribing index indicates the num-
ber of British National Formulary chapters from which
patients received prescriptions (excluding anti-dementia
drugs, vaccines and anaesthetics). This is a good measure
for comorbidity [25].
Analysis
We analysed data using Stata version 13.1 (Stata Corp,
College Station, Texas). For the period 2002–13, we esti-
mated overall rates of initiation and prescribing prevalence
of antipsychotics, hypnotics and anxiolytics; surgery consul-
tations, annual blood pressure monitoring, annual weight
monitoring and annual dementia review. We used
C. Cooper et al.
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multivariable Poisson regression to investigate the relation-
ship between deprivation, gender and these outcomes.
Random effects for general practices were included in mod-
els to account for variation in individual practices.
Comparisons were made to the cohort of patients without
dementia. Stratifying by Townsend quintile, incidence rate
ratios were calculated for outcomes comparing the demen-
tia cohort to the comparator non-dementia cohort.
Results
Included patients
A cohort of 68,061 patients was identiﬁed who had a
record of dementia while aged 50 or over during the period
2002–13 (Supplementary data, Figure S1, available in Age
and Ageing online); these patients were included in the ana-
lyses on psychotropic drug initiation. Of these, data were
available from 54,721 (80%) for at least 6 months of
follow-up, and so were included in the analyses on psycho-
tropic drug prescribing prevalence and healthcare contact
outcomes (Table 1). We included 259,337 people in our
control population without dementia.
Prescribing of psychotropic medication
The proportion of the 54,721 patients receiving at least one
prescription in a calendar year increased up to 2009, but
declined thereafter for antipsychotics, hypnotics and anxio-
lytics (Supplementary data, Figure S2(a)–(c) available in Age
and Ageing). During 2013, 3.1% of the 21,716 under follow-
up were prescribed antipsychotics, 2.4% were prescribed
hypnotics and 2.6% were prescribed anxiolytics. During
2009, when the psychotropic drug prescribing prevalence
was highest, 14.1% of the 16,043 then under follow-up were
prescribed antipsychotics, 10.6% were prescribed hypnotics
and 7.5% were prescribed anxiolytics. The proportion pre-
scribed antipsychotics ranged from 6.8% to 8.0% in the
deprivation groups; however, there was no systematic rela-
tionship between Townsend quintile and current prescribing
of antipsychotics (Table 2). Women with dementia were
more likely to be currently prescribed psychotropic medica-
tion than men with dementia. For example, 6.3% of men
were currently receiving antipsychotics, compared to 7.7% of
women, with an adjusted IRR (95% CI) of 1.18 (1.13–1.23).
Initiation of psychotropic medication
Overall, there was no systematic association between social
deprivation and the initiation of antipsychotics, hypnotics or
anxiolytics (Supplementary data, Table S1 available in Age
and Ageing). Men with dementia were more likely to initiate
all types of psychotropic medication than women with
dementia.
Consultations and healthcare monitoring in people
with dementia
The overall rate of surgery consultations was 6.8 visits per
year, with no systematic change over time (Supplementary
data, Figure S2(g) available in Age and Ageing). Annual blood
pressure and weight monitoring both increased over time,
and of the 21,716 patients who were under follow-up during
2013, blood pressure was recorded in 17,201 (79%) and
weight was recorded in 10,118 (47%) (Supplementary data,
Figure S2(d)–(e) available in Age and Ageing). From introduc-
tion in 2006, consistently around half of patients had a record
of receiving an annual dementia review (Supplementary data,
Figure S2(f) available in Age and Ageing). The crude rates and
proportions of these outcomes were similar across depriv-
ation score quintiles (Supplementary data, Figure S2 available
in Age and Ageing; Table 3). Of the 11,273 patients with a
dementia review during 2013, 5,657 (50%) had both weight
and blood pressure recorded during that year: of the 10,443
patients under follow-up in 2013 who did not have a demen-
tia review, 3,832 (37%) had both weight and blood pressure
recorded during that year.
Compared to men, women had lower rates of surgery
consultations (6.5 per person-year in women and 7.3 per
person-year in men; adjusted IRR 0.90, 95% CI 0.90–0.91),
of annual blood pressure monitoring (72% in women and
75% in men; adjusted IRR 0.96, 95% CI 0.95–0.97) and of
annual weight monitoring (36% in women and 41% in
men; adjusted IRR 0.91, 95% CI 0.90–0.93).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Characteristics of the included patients at ﬁrst
record of dementia
Characteristic Number (%)
Patients 68,061
Sex
Male 25,226 (37%)
Female 42,835 (63%)
Age (years)
50–59 1,344 (2%)
60–69 5,664 (8%)
70–79 20,678 (30%)
80–84 17,724 (26%)
85–89 14,652 (22%)
90+ 7,999 (12%)
Country
England 52,087 (77%)
Scotland 9,576 (14%)
Wales 4,260 (6%)
Northern Ireland 2,138 (3%)
Calendar year
2002–05 16,320 (24%)
2006–09 22,851 (34%)
2010–13 28,890 (42%)
Townsend quintile
1 (least deprived) 16,242 (24%)
2 15,366 (23%)
3 15,091 (22%)
4 12,976 (19%)
5 (most deprived) 8,386 (12%)
Prescribing index
Median (IQR) 4 (2–6)
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Table 2. IRRs for prescribing prevalence of antipsychotics, hypnotics and anxiolytics in 54,721 people with dementia, obtained from Poisson regression models with
GP practice ﬁtted as a random effecta,b
Covariate Antipsychotics Hypnotics Anxiolytics
% Univariable IRR (95% CI) Multivariable IRR (95% CI) % Univariable IRR (95% CI) Multivariable IRR (95% CI) % Univariable IRR (95% CI) Multivariable IRR (95% CI)
Townsend quintile
(least deprived)
1 7.0 1 1 5.5 1 1 3.9 1 1
2 7.1 0.98 (0.92–1.03) 0.97 (0.92–1.03) 5.8 1.04 (0.98–1.11) 1.03 (0.97–1.10) 4.6 1.07 (0.99–1.15) 1.06 (0.99–1.14)
3 8.0 1.07 (1.01–1.13) 1.07 (1.01–1.13) 5.5 0.96 (0.90–1.03) 0.96 (0.90–1.03) 4.6 1.08 (1.00–1.16) 1.07 (1.00–1.16)
4 6.8 0.95 (0.89–1.02) 0.95 (0.89–1.01) 5.2 0.96 (0.90–1.04) 0.96 (0.89–1.03) 3.8 0.92 (0.85–1.01) 0.92 (0.85–1.00)
(most deprived)
5 7.2 0.93 (0.87–1.00) 0.93 (0.87–1.00) 5.5 1.00 (0.92–1.08) 0.99 (0.91–1.07) 4.5 1.03 (0.94–1.13) 1.02 (0.93–1.12)
Sex
Male 6.3 1 1 5.1 1 1 3.9 1 1
Female 7.7 1.17 (1.13–1.22) 1.18 (1.13–1.23) 5.7 1.08 (1.04–1.13) 1.06 (1.02–1.12) 4.5 1.11 (1.05–1.16) 1.13 (1.07–1.19)
Age
50–69 4.7 0.61 (0.56–0.66) 0.61 (0.56–0.67) 2.9 0.52 (0.47–0.58) 0.52 (0.47–0.58) 3.0 0.64 (0.58–0.72) 0.64 (0.58–0.72)
70–79 7.9 1 1 5.8 1 1 4.7 1 1
80–84 7.3 0.89 (0.85–0.94) 0.89 (0.84–0.93) 5.7 0.95 (0.90–1.01) 0.95 (0.90–1.01) 4.3 0.88 (0.83–0.94) 0.87 (0.82–0.93)
85–89 7.2 0.87 (0.83–0.92) 0.83 (0.79–0.88) 5.8 0.96 (0.91–1.02) 0.94 (0.88–0.99) 4.2 0.86 (0.80–0.92) 0.82 (0.76–0.87)
90+ 7.2 0.86 (0.81–0.91) 0.82 (0.77–0.87) 5.9 0.98 (0.92–1.05) 0.96 (0.90–1.03) 4.2 0.84 (0.77–0.90) 0.79 (0.73–0.85)
Current year
2002–05 2.9 0.43 (0.39–0.46) 0.42 (0.39–0.46) 2.4 0.46 (0.42–0.50) 0.46 (0.42–0.50) 1.3 0.29 (0.25–0.32) 0.28 (0.25–0.32)
2006–09 9.4 1.33 (1.28–1.38) 1.32 (1.27–1.38) 7.1 1.32 (1.26–1.38) 1.32 (1.26–1.38) 4.8 0.99 (0.94–1.04) 0.98 (0.93–1.03)
2010–13 6.9 1 1 5.3 1 1 4.7 1 1
aRate per 100 person-years.
bEstimates from multivariable models adjusted for all other covariates, as well as for country.
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Table 3. IRRs for each of the four healthcare contact outcomes in 54,721 people with dementia, from Poisson regression models with GP practice ﬁtted as a random
effect
Covariate Surgery consultations Blood pressure monitoring Weight monitoring Annual dementia review (for follow-up 2006
onwards)
Ratea Univariable
IRR (95% CI)
Multivariableb
IRR (95% CI)
% Univariable
IRR (95% CI)
Multivariableb
IRR (95% CI)
% Univariable
IRR (95% CI)
Multivariableb
IRR (95% CI)
% Univariable
IRR (95% CI)
Multivariableb
IRR (95% CI)
Townsend quintile
(least deprived)
1 6.8 1 1 72 1 1 37 1 1 46 1 1
2 6.8 1.00 (1.00–1.01) 1.00 (0.99–1.00) 72 1.00 (0.98–1.01) 0.99 (0.98–1.01) 37 0.99 (0.96–1.01) 0.99 (0.96–1.01) 47 0.99 (0.97–1.02) 0.99 (0.97–1.01)
3 6.8 1.01 (1.00–1.02) 1.00 (1.00–1.01) 73 1.01 (0.99–1.03) 1.01)1.00 (0.99–1.02) 38 0.99 (0.97–1.02) 1.00 (0.97–1.03) 46 0.98 (0.96–1.01) 0.98 (0.95–1.00)
4 6.8 1.03 (1.03–1.04) 1.02 (1.01–1.02) 74 1.02 (1.00–1.04) 1.01 (0.99–1.03) 39 1.02 (0.99–1.04) 1.01 (0.99–1.04) 47 0.97 (0.94–0.99) 0.96 (0.94–0.99)
(most deprived)
5 6.5 1.02 (1.01–1.03) 1.00 (0.99–1.01) 75 1.03 (1.01–1.05) 1.02 (1.00–1.04) 40 1.02 (0.99–1.06) 1.02 (0.99–1.05) 48 0.97 (0.94–1.00) 0.97 (0.94–1.00)
Sex
Male 7.3 1 1 75 1 1 41 1 1 46 1 1
Female 6.5 0.89 (0.89–0.89) 0.90 (0.90–0.91) 72 0.97 (0.96–0.98) 0.96 (0.95–0.97) 36 0.87 (0.86–0.89) 0.91 (0.90–0.93) 47 1.02 (1.00–1.03) 1.01 (0.99–1.03)
Age
50–59 6.7 0.94 (0.93–0.96) 0.99 (0.97–1.00) 61 0.83 (0.78–0.87) 0.84 (0.80–0.89) 41 0.96 (0.90–1.03) 0.97 (0.91–1.04) 38 0.84 (0.78–0.90) 0.84 (0.78–0.91)
60–69 6.6 0.94 (0.94–0.95) 0.99 (0.98–0.99) 67 0.91 (0.89–0.94) 0.93 (0.90–0.95) 42 0.99 (0.96–1.03) 1.00 (0.97–1.03) 39 0.93 (0.90–0.96) 0.94 (0.90–0.97)
70–79 7.2 1 1 73 1 1 42 1 1 44 1 1
80–84 7.1 0.97 (0.96–0.97) 0.96 (0.95–0.96) 75 1.02 (1.00–1.04) 1.01 (1.00–1.03) 39 0.91 (0.89–0.93) 0.91 (0.89–0.93) 48 1.03 (1.01–1.05) 1.02 (1.00–1.04)
85–89 6.6 0.90 (0.90–0.91) 0.88 (0.88–0.89) 74 1.01 (1.00–1.03) 1.00 (0.98–1.01) 34 0.81 (0.79–0.83) 0.79 (0.77–0.81) 49 1.05 (1.03–1.07) 1.04 (1.02–1.06)
90+ 5.9 0.81 (0.80–0.81) 0.79 (0.78–0.79) 72 0.99 (0.97–1.01) 0.97 (0.95–0.99) 30 0.70 (0.68–0.72) 0.68 (0.66–0.70) 50 1.06 (1.03–1.08) 1.04 (1.01–1.06)
Current year
2002–05 6.7 0.96 (0.95–0.97) 1.03 (1.02–1.03) 64 0.83 (0.81–0.84) 0.85 (0.84–0.87) 24 0.56 (0.55–0.58) 0.57 (0.55–0.59) – – –
2006–09 6.6 0.96 (0.96–0.97) 1.00 (1.00–1.01) 72 0.93 (0.92–0.94) 0.95 (0.94–0.96) 35 0.80 (0.79–0.82) 0.81 (0.80–0.83) 41 0.80 (0.78–0.81) 0.80 (0.79–0.82)
2010–13 6.9 1 1 77 1 1 43 1 1 50 1 1
aRate per person-year.
bEstimates from multivariable models adjusted for all other covariates, as well as for country and prescribing index.
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Comparator cohort of patients without dementia
Rates of initiation of antipsychotics, hypnotics and anxioly-
tics were higher overall in the dementia cohort compared to
the non-dementia cohort (Supplementary data, Table S2
available in Age and Ageing). People with dementia had fewer
surgery consultations and were less likely to have their
weight and blood pressure monitored at least annually, com-
pared to the non-dementia group, with similar differences in
each of the Townsend quintile strata (Supplementary data,
Table S2 available in Age and Ageing).
Discussion
Area-level deprivation was not associated with healthcare or
psychotropic medication receipt in people with dementia.
Only half of people with dementia received an annual
review as reimbursed by QOF. Among people with demen-
tia, female gender was associated with receiving fewer pri-
mary care surgery consultations and less health monitoring.
Men with dementia were more likely to be initiated on psy-
chotropic drugs, but less likely to be currently taking them.
Compared with our control population, people with demen-
tia had fewer primary care consultations and were less likely
to have weight and blood pressure monitored annually, des-
pite the association of dementia with vascular risk factors,
frailty and malnutrition [1], and were more likely to receive
psychotropic medications.
Our ﬁndings differ from general population studies that
found higher psychotropic prescribing levels in more
deprived areas in people without dementia [26]. Perhaps
government policies in the past decade, including targets
incentivising GPs to identify and review annually people
with dementia may have reduced inequities. One interpret-
ation of our ﬁndings is that people with dementia, not hav-
ing a family or friend carer to facilitate appointments may
be the most important barrier to care, rather than socio-
economic constraints per se. Interventions to increase under-
standing of dementia carers about the importance of main-
taining physical health and treating co-morbidities may
therefore be an important public health intervention.
Socio-economic prescribing inequalities often arise
because patients or carers from less deprived groups better
negotiate healthcare systems to seek out more desirable treat-
ments. Socio-economic gradients in psychotropic prescribing
have been attributed to differential access to alternate ser-
vices such as psychological therapies, or different patient or
carer expectations [26]. Perhaps this did not happen in peo-
ple with dementia because there are few psychological, evi-
dence based, routinely available treatments for behavioural
and psychological symptoms of dementia [27], or because of
the serious risks of initiating psychotropic drugs in dementia,
although we did not ﬁnd inequity before the MHRA warn-
ings in 2009 [12]. In a previous study exploring the likelihood
of patients with physical health complaints being referred to
secondary care, inequalities associated with socio-economic
circumstances occurred more in the absence of explicit
guidance, whereas inequalities with older age and female gen-
der were evident for all conditions [28].
Having a dementia diagnosis predicted receipt of fewer
physical health checks and primary care contacts, despite
the National Dementia Strategies prioritising healthcare
access in this group. People with dementia often experience
difﬁculties arranging, remembering and attending appoint-
ments. Women with dementia are reported to have more
disability and disease than men with dementia [29], so it is
concerning that they receive less health monitoring. Despite
this, women were no less likely to receive an annual demen-
tia review, suggesting that the content of reviews should be
investigated, as preventative health monitoring should be an
important component. Women more often live alone, due
to their greater longevity [30]. The lesser likelihood of hav-
ing a co-resident carer might explain why women with
dementia access healthcare less.
Compared to men, women with dementia were less
likely to be initiated on psychotropic medication, but overall
more of these medications were prescribed to women indi-
cating they took them for longer. More regular medication
review could reduce unnecessary psychotropic prescribing.
As we found that men accessed healthcare more frequently,
there may have been more opportunities for review and
reduction where possible in line with current guidelines
[13]. In the general population, women are also more likely
than men to be prescribed psychotropic medication [31, 32].
Limitations
Surgery contacts might be lower in people with dementia
because they receive more home visits. We did not include
home visits in analyses as there is uncertainty about how well
they are recorded. Measures other than weight might be used
to assess malnutrition on home visits. We could not identify
people with undiagnosed dementia or control for dementia
severity. As area-level deprivation can reduce access to sec-
ondary care where most dementia is diagnosed, there may
have been more undiagnosed dementia in deprived areas; if
this were so, it is likely that early-stage dementia would be
most frequently missed due to symptom misattribution and
delayed help-seeking [33]. This could mean that the people in
more deprived areas had, on average, more severe dementia,
but we did not ﬁnd higher rates of psychotropic prescribing
in these areas that might have suggested this. Women are
more likely to move to a care home [34]. Those who remain
at home might therefore have dementia which is on average
less severe than men living at home. This could explain the
lower rate of surgery consultations by women. The use of an
area-level deprivation measure is a limitation, as individual
deprivation level will sometimes be at odds to the deprivation
level of the area in which a person lives.
Conclusion
Only half of people with dementia have an annual dementia
review recorded, as recommended in UK guidelines and
C. Cooper et al.
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QOF. The QOF review for dementia has been associated
with fewer unplanned hospital admissions, so increasing the
proportion of patients who receive this may improve health
outcomes [6]. In people with dementia, women received
less physical healthcare monitoring, surgery visits and pre-
scriptions for psychotropic drugs. A greater likelihood of
women living alone without a family carer to help them
access healthcare probably explains some of these ﬁndings.
Enabling variables, such as having a carer to facilitate
attending appointments have also been shown to be
important determinants of people with dementias’ health-
care access in ﬁndings from other developed countries [7].
Interventions to improve access to physical healthcare and
reduce psychotropic use in people with dementia, especially
women, could beneﬁt people with dementia, their families
and society by enabling them to live well with dementia for
longer.
Key points
• People with dementia received less primary, preventative
healthcare than people without dementia.
• Women with dementia received less primary, preventative
healthcare than men with dementia.
• Women with dementia were more likely to be taking psy-
chotropic medication than men with dementia.
Supplementary data
Supplementary data are available at Age and Ageing online.
Acknowledgements
This work was supported by The Dunhill Medical Trust
[grant number R296/0513].
Authors’ contributions
All authors devised the study; R.L. undertook all analyses
and R.L. and C.C. drafted the paper. All authors were part
of the Steering group that managed the study, of which
C.C. was Principal Investigator. All authors revised the
manuscript critically for intellectual content and approved
the ﬁnal version.
Conﬂicts of interest
None declared.
Ethics approval
The data provider of THIN (CSD Medical Research UK)
has obtained overall ethical approval from the South East
MREC. As we used anonymised routinely collected data in
this study, we did not require further ethics approval, but
we obtained approval by the THIN Scientiﬁc Review
Committee. We did not recruit, approach or interview indi-
vidual patients.
References
1. Poblador-Plou B, Calderon-Larranaga A, Marta-Moreno J
et al. Comorbidity of dementia: a cross-sectional study of pri-
mary care older patients. BMC Psychiatry 2014; 14:84.
2. Laitinen ML, Bell JS, Lavikainen P, Lonnroos E, Sulkava R,
Hartikainen S. Nationwide study of antipsychotic use among
community-dwelling persons with Alzheimer’s disease in
Finland. Int Psychogeriatr 2011; 23(10):1623–31.
3. Schulze J, Glaeske G, van den Bussche H et al. Prescribing of
antipsychotic drugs in patients with dementia: a comparison
with age-matched and sex-matched non-demented controls.
Pharmacoepidemiol Drug Saf 2013; 22(12):1308–16.
4. Barnes TR, Banerjee S, Collins N, Treloar A, McIntyre SM,
Paton C. Antipsychotics in dementia: prevalence and quality
of antipsychotic drug prescribing in UK mental health ser-
vices. Br J Psychiatry 2012; 201(3):221–6.
5. Luppa M, Luck T, Braehler E, Koenig HH, Riedel-HellerSG.
Prediction of institutionalisation in dementia - A systematic
review. Dementia and geriatric cognitive disorders 2008; 26
(1):65–78
6. Bordier L, Doucet J, Boudet J, Bauduceau B. Update on cog-
nitive decline and dementia in elderly patients with diabetes.
Diabetes Metab 2014; 40(5):331–7.
7. Ballard C, Margallo-Lana M, Juszczak E et al. Quetiapine and
rivastigmine and cognitive decline in Alzheimer’s disease: ran-
domised double blind placebo controlled trial. Br Med J
2005; 330(7496):874–7.
8. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland
D, Selbaek G. Short- and long-term mortality risk associated
with the use of antipsychotics among 26,940 dementia outpa-
tients: a population-based study. Am J Geriatr Psychiatry
2014 Apr; 22(4):321–31.
9. Sterke CS, van Beeck EF, van d Velde N et al. New insights:
dose-response relationship between psychotropic drugs and
falls: a study in nursing home residents with dementia. J Clin
Pharmacol 2012; 52(6):947–55.
10. Bierman EJM, Comijs HC, Gundy CM, Sonnenberg C, Jonker
C, Beekman ATF. The effect of chronic benzodiazepine use
on cognitive functioning in older persons: good, bad or indif-
ferent? Int J Geriatr Psychiatry 2007; 22(12):1194–200.
11. Rosenberg PB, Mielke MM, Han D et al. The association of
psychotropic medication use with the cognitive, functional,
and neuropsychiatric trajectory of Alzheimer’s disease. Int J
Geriatr Psychiatry 2012 Dec; 27(12):1248–57.
12. Medicines and Healthcare products Regulatory Agency
CoHM. Antipsychotics: use in elderly people with dementia.
Drug Saf Update 2009; 2: 8.
13. Banerjee S The Use of Antipsychotic Medication for People
with Dementia: Time for Action. London: Department of
Health, 2009.
14. Martinez C, Jones RW, Rietbrock S. Trends in the prevalence
of antipsychotic drug use among patients with Alzheimer’s
disease and other dementias including those treated with anti-
dementia drugs in the community in the UK: a cohort study.
BMJ Open 2013; 3(1):e002080.
Inequalities in receipt of mental and physical healthcare
399
Downloaded from https://academic.oup.com/ageing/article-abstract/46/3/393/2631398
by University of Portsmouth Library user
on 19 June 2018
15. Guthrie B, Clark SA, Reynish EL, McCowan C, Morales DR.
Differential impact of two risk communications on anti-
psychotic prescribing to people with dementia in Scotland:
segmented regression time series analysis 2001–2011. PLoS
One 2013; 8(7):e68976.
16. McIlroy G, Thomas SK, Coleman JJ. Second-generation anti-
psychotic drug use in hospital inpatients with dementia: the
impact of a safety warning on rates of prescribing. J Public
Health (Oxf) 2015; 37(2):346–52.
17. Hart JT. Inverse care law. Lancet 1971; 1(7696):405–&.
18. Cooper C, Lodwick R, Walters K et al. Observational cohort
study: deprivation and access to anti-dementia drugs in the
UK. Age Ageing 2016; 45(1):148–54.
19. Booth N. What are the Read Codes? Health Libr Rev 1994;
11: 177–82.
20. Horsfall L, Walters K, Petersen I. Identifying periods of
acceptable computer usage in primary care research data-
bases. Pharmacoepidemiol Drug Saf 2013; 22(1):64–9.
21. Maguire A, Blak BT, Thompson M. The importance of
deﬁning periods of complete mortality reporting for research
using automated data from primary care. Pharmacoepidemiol
Drug Saf 2009; 18(1):76–83.
22. Dave S, Petersen I. Creating medical and drug code lists to
identify cases in primary care databases. Pharmacoepidemiol
Drug Saf 2009; 18(8):704–7.
23. Townsend P, Phillimore, M, Beattie A Health and Deprivation:
Inequality and the North. London: Croom Helm, 1988.
24. Health and social care information centre. Dementia rule set.
Health and social care information centre 2014Available
from: URL: http://www.hscic.gov.uk/media/15374/Dementia-
rulesetv300/pdf/Dementia_ruleset_v30.0.pdf
25. Brilleman SL, Salisbury C. Comparing measures of multimor-
bidity to predict outcomes in primary care: a cross sectional
study. Fam Pract 2013; 30(2):172–8.
26. Shah SM, Carey IM, Harris T, DeWilde S, Cook DG.
Antipsychotic prescribing to older people living in care
homes and the community in England and Wales. Int J
Geriatr Psychiatry 2011; 26(4):423–34.
27. Livingston G, Kelly L, Lewis-Holmes E et al. A systematic
review of the clinical effectiveness and cost-effectiveness of
sensory, psychological and behavioural interventions for man-
aging agitation in older adults with dementia. Health Technol
Assess 2014; 18(39):1–vi.
28. McBride D, Hardoon S, Walters K, Gilmour S, Raine R.
Explaining variation in referral from primary to secondary
care: cohort study. Br Med J 2010: 341.
29. Collerton J, Davies K, Jagger C et al. Health and disease in
85 year olds: baseline ﬁndings from the Newcastle 85+
cohort study. BMJ 2009; 339: b4904.
30. Ofﬁce of National Statistics. Living alone in England and
Wales. Ofﬁce of National Statistics 2015. Available from: URL:
http://www.ons.gov.uk/ons/rel/census/2011-census-analysis/
do-the-demographic-and-socio-economic-characteristics-of-
those-living-alone-in-england-and-wales-differ-from-the-general-
population-/sty-living-alone-in-the-uk.html (10 October 2015,
date last accessed).
31. Cooper C, Bebbington P et al. The treatment of common mental
disorders across age groups: Results from the 2007 adult psychi-
atric morbidity survey. J Affect Disord 2010; 127(1–3):96–101.
32. Marston L, Nazareth I, Petersen I, Walters K, Osborn DP.
Prescribing of antipsychotics in UK primary care: a cohort
study. BMJ Open 2014; 4(12):e006135.
33. Feldman L, Wilcock J, Thuné-Boyle I, Iliffe S. Explaining the
effects of symptom attribution by carers on help-seeking for indi-
viduals living with dementia. Dementia 1471301215593185, ﬁrst
published on June 30, 2015. doi:10.1177/1471301215593185.
34. McCann M, Donnelly M, O’Reilly D. Living arrangements,
relationship to people in the household and admission to care
homes for older people. Age Ageing 2011 May; 40(3):358–63.
Received 16 February 2016; editorial decision 11 October
2016
C. Cooper et al.
400
Downloaded from https://academic.oup.com/ageing/article-abstract/46/3/393/2631398
by University of Portsmouth Library user
on 19 June 2018
